combined with other pharmaceutical
active substances" (page 11 of the description).
Linagliptin (BI 1356), a particularly preferred DPP-4
inhibitor of the present application ... DEVANSHU JOSHI
Signing Date:21.07.2022
10:49:18
enriching the art. Further, Linagliptin is characterized
by unique pharmacokinetics, such as with nonlinear
profile (less than
been filed by the patentee in respect of the
pharmaceutical preparations 'LINAGLIPTIN' and variants thereof, covered
by the granted patent. It is further ... embodiments being
marketed by the plaintiff no. 2 in India. The compound,
Linagliptin, covered and claimed by the suit patent was
invented upon further research
stated that the impugned patent includes the compound
'LINAGLIPTIN' which is the subject matter of the claims 2 to 7. It is
averred ... that the compound 'LINAGLIPTIN' is within the scope of the
Genus Patents being IN227719 and IN303351 which have a priority date
earlier than
various pharmaceutical preparations
including the compound known by the INN name 'Linagliptin'. The
revocation petitions have been opposed by the Patentee
various pharmaceutical preparations
including the compound known by the INN name 'Linagliptin'. The
revocation petitions have been opposed by the Patentee
relates to the same patent IN'243301 which covers the
compound Linagliptin.
5. The counter statement has been returned under objections. Let the
same
